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On November 13, 2015, the Immune Risk SRP, participants from the JSC, HQ, the NSBRI, and 
NRESS participated in a WebEx/teleconference.  The purpose of the call (as stated in the 
Statement of Task) was to allow the SRP members to: 
 
1. Receive an update from the Human Research Program (HRP) Chief Scientist (or 
designee) on the status of NASA’s current and future exploration plans and the impact 
these will have on the HRP. 
2. Receive an update on any changes within the HRP since the 2014 SRP meeting. 
3. Receive an update by the Element or Project Scientist(s) since the 2014 SRP meeting. 
4. Participate in a discussion with the HRP Chief Scientist (or designee) and the Element 
regarding possible topics to be addressed at the next SRP meeting. 
 
Based on the presentations and the discussion during the WebEx/teleconference, the SRP would 
like to relay the following information to Dr. Shelhamer, the HRP Chief Scientist. 
 
1. The SRP thought the WebEx/teleconference was very informative and appreciated the 
presentations from Dr. Perchonok, Dr. Norsk and Dr. Crucian. 
 
2. It is the SRPs understanding that the HRP management recognizes and supports the need 
for integrated projects that involve work under the aegis of various SRPs.  From what the 
SRP has been told, there have been multiple meetings that bring representatives from the 
various SRPs to advise on development of interdisciplinary research directions.  Given 
that we firmly believe that immunology and optimized inflammation mechanisms are at 
the core of astronaut health, we are concerned that, to date, the Immune Risk SRP has not 
participated in any of these interdisciplinary SRP meetings.  While we were told during 
our meeting about several ongoing and planned interdisciplinary projects that involve the 
JSC immunology team(s), it is a concern to us that our input seems a posteriori regarding 
integrated research directions. 
 
3. There is concern about the lack of uniformity in the design and implementation of more 
standardized assay methodology to characterize the astronaut immune responses before, 
during and after spaceflight.  The collaborative studies presented, as well as other 
proposed ancillary studies use methodology that is distinct enough to warrant questions 
about comparing the data.  For example, there are immune studies that use either whole 
blood or semi purified peripheral blood mononuclear cells.  Dr. Crucian presented lucid 
and compelling arguments of why one versus the other sample is preferred.  Yet the 
collaborative studies described continue to use both cell sources which are NOT directly 
comparable.  To respect research colleagues who have developed their own assay 
conditions for their own laboratories is certainly understandable from a science ethics 
point of view.  Yet, given the highly limited and precious nature of the astronaut samples 
that are being obtained and the statistical suppositions that have to be made with such 
small sample sizes, it is critical that further variation from methodological differences be 
minimized.  Given that the JSC Immunology team lead by Dr. Crucian is the custodian of 
these samples, his group should dictate the samples that will be used and the assays that 
will be performed in as identical assay settings as possible.  This is not to criticize the 
capabilities or expertise of others – it is to say that inter assay accuracy and inter 





laboratory precision do not translate across different methodologies or different 
laboratories. 
 
4. Again, the SRP is concerned about data analysis methodology and continues to urge for 
collaboration with systems biologists who have expertise in immunology to better 
characterize the immune risks of spaceflight. 
 
5. Lastly, in future meetings, the SRP would like the presentations to clearly show what 
integration is currently going on with other HRP groups instead of having to ask for that 
information. 
 
